106191-02-0

Basic information

• Product Name: (2S)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINE
• Synonyms: (2S)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINE;L-O-TBDMS-PYROGLUTAMINOL;(S)-5-((tert-butyldiMethylsilyloxy)Methyl)pyrrolidin-2-one;(5S)- 5-[[[(1,1-diMethylethyl)diMethylsilyl]oxy]Methyl]-2-Pyrrolidinone;(5S)-5-[[[(tert-butyl)dimethylsilyl]oxy]methyl]pyrrolidin-2-one;(5S)-5-[[[(tert-Butyl)dimethylsilyl]oxy]methyl]-2- pyrrolidinone;(5S)-5-[[[(tert-Butyl)dimethylsilyl]oxy]methyl]-2-pyrrolidinone,99%e.e.
• CAS NO: 106191-02-0
• Molecular Formula: C₁₁H₂₃NO₂Si
• Molecular Weight: 229.4
• Mol File: 106191-02-0.mol
• Article Data: 68

Chemical Properties

• Boiling Point: 307.6±15.0 °C(Predicted)
• Appearance: /
• Density: 0.942±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 15.90±0.40(Predicted)
• CAS DataBase Reference: (2S)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINE(106191-02-0)
• EPA Substance Registry System: (2S)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINE(106191-02-0)

Safety Data

• Hazardous Substances Data: 106191-02-0(Hazardous Substances Data)

Usage

General Description

The chemical compound (2S)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-oxo-1-pyrrolidine is a synthetic compound with a complex structure. It is a pyrrolidine derivative with a silyl group attached to the oxygen atom and a carbonyl group at the 5th position. (2S)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINE is commonly used in organic synthesis as a reagent or building block for the preparation of various pharmaceuticals and other organic compounds. It may also have potential applications in the field of medicinal chemistry and drug development. This chemical compound is important for research and development in the pharmaceutical industry.

Upstream product

• 7149-65-7 ethyl (S)-pyroglutamate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 39538-20-0 (S)-2-tert-Butoxycarbonylamino-pentanedioic acid 1-(2,5-dioxo-pyrrolidin-1-yl) ester 5-methyl ester 
• 126587-35-7 methyl (4S)-4-[(tert-butoxy)carbonylamino]-5-hydroxypentanoate 
• 45214-91-3 (2S)-2-[(tert-butoxy)carbonylamino]-4-(methoxycarbonyl)butanoic acid 
• 4931-66-2 methyl (S)-pyroglutamate 
• 56-86-0 L-glutamic acid 
• 74936-93-9 (S)-5-oxopyrrolidine-2-carbonyl chloride 
• 98-79-3 L-Pyroglutamic acid 
• 17342-08-4 (S)-Pyroglutaminol 
• 96014-55-0 Methyl (4S)-4-(N-(tert-Butoxycarbonyl)amino)-5-((tert-butyldimethylsilyl)oxy)pentanoate 
• 13515-99-6 D-glutamic acid dimethyl ester hydrochloride 
• 4042-36-8 D-pyrrolidone-5-carboxylic acid 
• 96914-00-0 C₅H₇NO₂ 

Downstream Products

• 685896-43-9 (3-{[(2R)-2-({[tert-butyl-(dimethyl)-silyl]-oxy}-methyl)-5-oxopyrrolidin-1-yl]-methyl}-phenyl)-acetonitrile 
• 685896-32-6 methyl (2E)-3-(2-{[(2R)-2-({[tert-butyl-(dimethyl)-silyl]-oxy}-methyl)-5-oxopyrrolidin-1-yl]-methyl}-phenyl)-prop-2-enoate 
• 153870-09-8 (S)-1-(benzyloxycarbonyl)-5-[(tert-butyldimethylsilyl)oxymethyl]-2-pyrrolidinone 
• 109021-54-7 (S)-5-(tert-butyldimethylsilyloxymethyl)-1-(phenylmethyl)-2-pyrrolidinone 
• 81658-26-6 tert-butyl (S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidin-1-carboxylate 
• 128811-31-4 tert-butyl (2R)-2-<<(tert-butyl)dimethylsilyloxy>methyl>-5-oxopyrrolidine-1-carboxylate 
• 1622235-66-8 (2S,3R)-3-(3-(benzyloxy)-5-carboxyphenyl)pyrrolidine-2-carboxylic acid hydrochloride 
• 1622235-65-7 (2S,3R)-3-(3-carboxy-5-propoxyphenyl)pyrrolidine-2-carboxylic acid hydrochloride 
• 1622235-85-1 (2S,3R)-3-(3-([1,1′-biphenyl]-3-ylmethoxy)-5-carboxyphenyl)-1-(tert-butoxycarbonyl)-pyrrolidine-2-carboxylic acid 
• 1622154-08-8 (2S,3R)-3-(3-(benzyloxy)-5-carboxyphenyl)-1-(tert-butoxycarbonyl)-pyrrolidine-2-carboxylic acid 
• 1622235-84-0 (2S,3R)-1-(tert-butoxycarbonyl)-3-(3-carboxy-5-propoxyphenyl)-pyrrolidine-2-carboxylic acid 
• 1622235-81-7 (2S,3R)-tert-butyl 3-(3-([1,1′-biphenyl]-3-ylmethoxy)-5-(hydroxymethyl)phenyl)-2-(hydroxymethyl)-pyrrolidine-1-carboxylate 
• 1622235-80-6 (2S,3R)-tert-butyl 3-(3-(benzyloxy)-5-(hydroxymethyl)phenyl)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 1622235-79-3 (2S,3R)-tert-butyl 2-(hydroxymethyl)-3-(3-(hydroxymethyl)-5-propoxyphenyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

Multi-gram synthesis of enantiopure 1,5-disubstituted tetrazoles via Ugi-azide 3-component reaction

Tetrazoles have been widely studied for their biological properties. An efficient route for large-scale synthesis of 1,5-disubstituted tetrazoles (1,5-DTs) is presented. The strategy exploits a reductive approach to synthetize a cyclic chiral imine substrate which is then converted into the target product through an Ugi-azide three-component reaction (UA-3CR). The final products are equipped with additional functionalities which can be further elaborated for the generation of combinatorial libraries of enantiopure heterocycles.

A cascade strategy enables a total synthesis of (-)-gephyrotoxin

A concise and efficient synthesis of (-)-gephyro-toxinfrom L-pyroglutaminol has been realized. The key step in this approach is a diastereoselective intramolecular enamine/ Michael cascade reaction that forms two rings and two stereocenters and generates a stable tricyclic iminium cation. A hydroxy-directed reduction of this intermediate plays a key role in establishing the required cis-decahydroquinoline ring system, enabling the total synthesis of (-)-gephyrotoxin in nine steps and 14 % overall yield. The absolute configuration of the synthetic material was confirmed by single-crystal X-ray diffraction and is consistent with the structure originally proposed for material isolated from the natural source.

Diastereoselective Diboration of Cyclic Alkenes: Application to the Synthesis of Aristeromycin

The Pt-catalyzed diboration of cyclic alkenes is extended to unsaturated heterocycles and bicyclic compounds and can be accomplished in a diastereoselective fashion. The optimal procedures, substrate scope, and diastereoselectivity were investigated, and examples employing both homogeneous and heterogeneous catalysis were examined. Lastly, application to the construction of the nucleoside analog (±)-aristeromycin was conducted.

INHIBITORS OF APOL1 AND METHODS OF USING SAME

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).